-
公开(公告)号:US20090226925A1
公开(公告)日:2009-09-10
申请号:US12424087
申请日:2009-04-15
申请人: Stefan K.G. Grebe , Mark R. Pittelkow , Kevin C. Halling , Aleksandar Sekulic , Kendall W. Cradic , Ming Mai
发明人: Stefan K.G. Grebe , Mark R. Pittelkow , Kevin C. Halling , Aleksandar Sekulic , Kendall W. Cradic , Ming Mai
CPC分类号: C12Q1/6886 , C12Q2600/156
摘要: Nucleic acids and methods for amplifying and detecting mutant BRAF sequences are provided herein. In particular, nucleic acids and methods for amplifying and detecting BRAF sequences that encode the V600E BRAF mutant are provided herein.
摘要翻译: 本发明提供了用于扩增和检测突变型BRAF序列的核酸和方法。 特别地,本文提供用于扩增和检测编码V600E BRAF突变体的BRAF序列的核酸和方法。
-
公开(公告)号:US20070020657A1
公开(公告)日:2007-01-25
申请号:US11437541
申请日:2006-05-19
申请人: Stefan Grebe , Mark Pittelkow , Kevin Halling , Aleksandar Sekulic , Kendall Cradic , Ming Mai
发明人: Stefan Grebe , Mark Pittelkow , Kevin Halling , Aleksandar Sekulic , Kendall Cradic , Ming Mai
CPC分类号: C12Q1/6886 , C12Q2600/156
摘要: Nucleic acids and methods for amplifying and detecting mutant BRAF sequences are provided herein. In particular, nucleic acids and methods for amplifying and detecting BRAF sequences that encode the V600E BRAF mutant are provided herein.
摘要翻译: 本发明提供了用于扩增和检测突变型BRAF序列的核酸和方法。 特别地,本文提供用于扩增和检测编码V600E BRAF突变体的BRAF序列的核酸和方法。
-
公开(公告)号:US09180136B2
公开(公告)日:2015-11-10
申请号:US13274058
申请日:2011-10-14
IPC分类号: A61K31/6615 , C12Q1/68 , G01N21/64 , C40B30/04 , G01N33/573 , C40B40/06 , A61P35/00 , G01N33/574
CPC分类号: A61K31/6615 , A61K9/0014 , C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158 , G01N33/57492
摘要: The present invention relates to methods of selectively treating a patient with skin squamous cell carcinoma are disclosed. Specifically, the methods comprise assessing whether or not the tumor will be responsive to IP6 treatment by using reduced INPP5A expression level as an indicator. The present invention further provides methods of assessing the progression of the disease, and kits that facilitate these methods as disclosed.
摘要翻译: 本发明涉及选择性治疗患有皮肤鳞状细胞癌的患者的方法。 具体而言,该方法包括通过使用降低的INPP5A表达水平作为指标来评估肿瘤是否对IP6治疗有反应。 本发明还提供了评估疾病进展的方法,以及促进所公开的这些方法的试剂盒。
-
-